Publications by the researcher in collaboration with Manuel Barreiro de Acosta (29)

2024

  1. Efficacy and safety of biological treatment for inflammatory bowel disease in elderly patients: Results from a GETECCU cohort

    Gastroenterologia y Hepatologia

  2. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on sexuality and inflammatory bowel disease

    Gastroenterologia y Hepatologia

2023

  1. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

    Clinical Gastroenterology and Hepatology, Vol. 21, Núm. 3, pp. 771-788.e10

  2. Is Occupation a Risk Factor for Developing Inflammatory Bowel Disease? A Case–Control Study

    Crohn's and Colitis 360, Vol. 5, Núm. 4

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  3. Radon exposure and inflammatory bowel disease in a radon prone area

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 7, pp. 405-409

  4. Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 3, pp. 165-176

  5. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Impact of biological agents on postsurgical complications in inflammatory bowel disease: A multicentre study of geteccu

    Journal of Clinical Medicine, Vol. 10, Núm. 19

  2. Recommendations of the Spanish Working Group on Crohn's disease and Ulcerative Colitis (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa — GETECCU) on dysplasia screening in inflammatory bowel disease patients

    Gastroenterologia y Hepatologia, Vol. 44, Núm. 6, pp. 435-447

2019

  1. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

    Therapeutic Advances in Gastroenterology, Vol. 12

  2. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients

    Digestive Diseases and Sciences, Vol. 64, Núm. 3, pp. 846-854

2016

  1. Tuberculosis in anti-tumour necrosis factortreated inflammatory bowel disease patients after the implementation of preventive measures: Compliance with recommendations and safety of retreatment

    Journal of Crohn's and Colitis, Vol. 10, Núm. 10

2015

  1. Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn's disease: Predictors of efficacy in clinical practice

    European Journal of Gastroenterology and Hepatology, Vol. 27, Núm. 4, pp. 430-435

  2. Influence of urban/rural and coastal/inland environment on the prevalence, phenotype, and clinical course of inflammatory bowel disease patients from northwest of Spain: A cross-sectional study

    European Journal of Gastroenterology and Hepatology, Vol. 27, Núm. 9, pp. 1030-1037

2014

  1. Drug trough levels and primary nonresponse to antiTNF therapy in moderate-severe Crohn disease

    Gastroenterology, Vol. 146, Núm. Suppl. 1, pp. 247

  2. The complete picture of changing pediatric inflammatory bowel disease incidence in Spain in 25years (1985-2009): The EXPERIENCE registry

    Journal of Crohn's and Colitis, Vol. 8, Núm. 8, pp. 763-769

2013

  1. Increasing incidence of pediatric inflammatory bowel disease in Spain (1996-2009): The SPIRIT registry

    Inflammatory Bowel Diseases, Vol. 19, Núm. 1, pp. 73-80

  2. New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease patients

    Pharmacogenomics, Vol. 14, Núm. 6, pp. 631-640